CClinicalTrials.gg
Status unknownNCT02459509Updated Apr 18, 2016

A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children

A Phase 4 interventional study of Dexmedetomidine in Anxiety, Separation, sponsored by The University of Hong Kong. Status unknown at 1 site in Hong Kong. Open to participants aged 6 Months to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-18.

Sponsored by The University of Hong Kong · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
6 Months to 5 Years
Sex
All
01

Study summary

The purpose of the study is to determine if 4mcg/kg of intranasal dexmedetomidine is better than 2mcg/kg in successfully sedating a child prior to induction of anesthesia.

Read the detailed description

Dexmedetomidine is a selective alpha-2 adrenoreceptor agonist that has sedative, anxiolytic and analgesic properties without causing respiratory depression. It has been administered safely and effectively via a number of routes including as an intravenous infusion, intramuscularly, intranasally, buccally and orally .

Yuen et al established that the median time of onset of sedation is 25-30 minutes, making it an ideal agent for preoperative sedation. The same group also studied doses of 1 mcg/kg and 2 mcg/kg as a sedative premedication and found that the success rates of appropriate sedation at induction in children aged 1 to 8 years were 53% and 66% respectively, with a dose related increase in successful sedation.

Much higher doses of dexmedetomidine have also been used safely. Administered intravenously, 3mcg/kg of dexmedetomidine has been shown to provide satisfactory sedation for paediatric MRI in 97% of cases, without adverse effects.

The investigators aim to show that high dose intranasal dexmedetomidine is a safe, effective and an easily administered sedative premedication.

The investigators hypothesise that 4mcg/kg compared to 2mcg/kg of intranasal dexmedetomidine will lead to at least a 20% increase in the proportion of satisfactorily sedated patients at the time of anaesthesia induction.

The primary outcome will be the proportion of children with satisfactory sedation at the time of anaesthesia induction.

Suitable patients will be identified from the theatre lists and consent will be sought from their legal guardians during preassessment clinic or during their anaesthetic preoperative assessment on the ward.

In a previous study, 66% of children aged 1-5 years were satisfactorily sedated at the time of induction with 2 mcg/kg of intranasal dexmedetomidine. In order to find a 20% difference with 4 mcg/kg of dexmedetomidine, the investigators' sample size needs to be 140 (70 in each group), for a power of 0.8 and a 5% false positive rate.

The demographic data will be analysed by t test and chi-square test. The proportions of satisfactory sedation will be analysed by chi-square test. The onset sedation time and duration of sedation will be analysed by survival analysis. The vital signs over times will be expressed by percentage changes from baseline and estimated by mean and standard errors. A p-value\<0.05 will be considered statistically significant.

02

Conditions studied

  • Anxiety, Separation

Browse trials for

Keywords

  • Sedation
  • dexmedetomidine
  • pediatric
  • preoperative period
03

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • All children of American Society of Anesthesiologists (ASA) physical status classification I or II (healthy) between the ages of 6 months and 5 years undergoing surgery at Queen Mary Hospital

Exclusion criteria

Exclusion Criteria:

  • Any patient receiving other sedative premedication, allergy to dexmedetomidine, organ dysfunction, cardiac arrhythmia and congenital heart disease.
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine 2 mcg/kg

    2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction

    Drug: Dexmedetomidine

  • Active comparator
    Dexmedetomidine 4 mcg/kg

    4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction

    Drug: Dexmedetomidine

Interventions

  • DrugDexmedetomidine

    Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation

    Also known as: Precedex

05

What researchers measure

Primary outcomes

  1. Satisfactory sedation

    The primary outcome will be the proportion of children with satisfactory sedation at the time of anaesthesic induction.

    Time frame: From 30 minutes post drug administration to induction of anaesthesia (average 30 minutes)

Secondary outcomes

  1. Time to satisfactory sedation

    Time taken from drug administration to when the child's sedation level is that of only responding after mild prodding or shaking

    Time frame: From time of drug administration to when Observer's Assessment of Alertness/ Sedation Score is 2 or less (from 0 minutes to 30 minutes)

  2. Blood pressure

    Blood pressure will be taken every 5 minutes

    Time frame: From drug administration to end of anaesthesia (on average 1 to 3 hours)

  3. Heart rate

    Heart rate will be taken every 5 minutes

    Time frame: From drug administration to end of anaesthesia (on average 1 to 3 hours)

  4. Oxygen saturations

    Oxygen saturations will be taken every 5 minutes

    Time frame: From drug administration to end of anaesthesia (on average 1 to 3 hours)

06

Study locations

1 of 1 sites recruiting
  • Queen Mary Hospital
    Hong Kong, Hong Kong
    • Sophie E Liu, MBBS · Contact · sophieliu@doctors.org.uk · 55086630
    • Theresa Hui, MBBS · Contact · huiwct@ha.org.hk · 95368149
    • Sophie E Liu, MBBS · Principal investigator
    • Theresa Hui, MBBS · Sub investigator
    • Grace Wong, MBBS · Sub investigator
    • Vivian Yuen, MBBS · Sub investigator
    • Michael G Irwin, MBChB · Sub investigator
    • Silky Wong, MBBS · Sub investigator
    Recruiting
07

References and documents

Publications

  • Pestieau SR, Quezado ZM, Johnson YJ, Anderson JL, Cheng YI, McCarter RJ, Choi S, Finkel JC. High-dose dexmedetomidine increases the opioid-free interval and decreases opioid requirement after tonsillectomy in children. Can J Anaesth. 2011 Jun;58(6):540-50. doi: 10.1007/s12630-011-9493-7. Epub 2011 Apr 2. PubMed 21461792 ↗
  • Mason KP, Zurakowski D, Zgleszewski SE, Robson CD, Carrier M, Hickey PR, Dinardo JA. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paediatr Anaesth. 2008 May;18(5):403-11. doi: 10.1111/j.1460-9592.2008.02468.x. Epub 2008 Mar 18. PubMed 18363626 ↗
  • Mason KP, Lubisch NB, Robinson F, Roskos R. Intramuscular dexmedetomidine sedation for pediatric MRI and CT. AJR Am J Roentgenol. 2011 Sep;197(3):720-5. doi: 10.2214/AJR.10.6134. PubMed 21862817 ↗
  • Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg. 2007 Aug;105(2):374-80. doi: 10.1213/01.ane.0000269488.06546.7c. PubMed 17646493 ↗
  • Yuen VM, Hui TW, Irwin MG, Yao TJ, Chan L, Wong GL, Shahnaz Hasan M, Shariffuddin II. A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. Anaesthesia. 2012 Nov;67(11):1210-6. doi: 10.1111/j.1365-2044.2012.07309.x. Epub 2012 Sep 5. PubMed 22950484 ↗
08

Registry details

Key details

Study ID
NCT02459509
Lead sponsor
The University of Hong Kong
Responsible party
Sponsor
First posted
Jun 2, 2015
Start date
Jun 2015
Primary completion
May 2016 (estimated)
Completion
May 2016 (estimated)
Last update
Apr 18, 2016

Study contacts

Sophie E Liu, MBBS
Contact
sophieliu@doctors.org.uk
852 55086630
Theresa Hui, MBBS
Contact
huiwct@ha.org.hk
852 95368149
Sophie E Liu, MBBS
principal investigator · Hong Kong University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion